Silvia Francisci1, Pamela Minicozzi2, Daniela Pierannunzio3, Eva Ardanaz4, Andrea Eberle5, Tom K Grimsrud6, Arnold Knijn7, Ugo Pastorino8, Diego Salmerón9, Annalisa Trama10, Milena Sant2. 1. Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanità, Rome, Italy. Electronic address: silvia.francisci@iss.it. 2. Department of Preventive and Predictive Medicine, Analytical Epidemiology and Health Impact Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 3. Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanità, Rome, Italy. 4. Navarre Public Health Institute, Pamplona, Spain; CIBER Epidemiology and Public Health CIBERESP, Spain. 5. Bremen Cancer Registry, Leibniz-Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany. 6. Department of Research, Cancer Registry of Norway, Oslo, Norway. 7. Data Management Sector, Istituto Superiore di Sanità, Rome, Italy. 8. Division of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. 9. CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain; Departamento de Ciencias Sociosanitarias, Universidad de Murcia, Spain. 10. Department of Preventive and Predictive Medicine, Evaluative epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Abstract
BACKGROUND: Survival of patients diagnosed with lung and pleura cancer is a relevant health care indicator which is related to the availability and access to early diagnosis and treatment facilities. Aim of this paper is to update lung and pleural cancer survival patterns and time trends in Europe using the EUROCARE-5 database. METHODS: Data on adults diagnosed with lung and pleural cancer from 87 European cancer registries in 28 countries were analysed. Relative survival (RS) in 2000-2007 by country/region, age and gender, and over time trends in 1999-2007 were estimated. RESULTS: Lung cancer survival is poor everywhere in Europe, with a RS of 39% and 13% at 1 and 5years since diagnosis, respectively. A geographical variability is present across European areas with a maximum regional difference of 12 and 5 percentage points in 1-year and 5-year RS respectively. Pleural cancer represents 4% of cases included in the present study with 7% 5-year RS overall in Europe. Most pleural cancers (83%) are microscopically verified mesotheliomas. Survival for both cancers decreases with advancing age at diagnosis for both cancers. Slight increasing trends are described for lung cancer. Survival over time is higher for squamous cell carcinoma and adenocarcinomas than for small and large cell carcinoma; and better among women than men. CONCLUSIONS: Despite the generalised although slight increase, survival of lung and pleural cancer patients still remains poor in European countries. Priority should be given to prevention, with tobacco control policies across Europe for lung cancer and banning asbestos exposure for pleural cancer, and in early diagnosis and better treatment. The management of mesothelioma needs a multidisciplinary team and standardised health care strategies.
BACKGROUND: Survival of patients diagnosed with lung and pleura cancer is a relevant health care indicator which is related to the availability and access to early diagnosis and treatment facilities. Aim of this paper is to update lung and pleural cancer survival patterns and time trends in Europe using the EUROCARE-5 database. METHODS: Data on adults diagnosed with lung and pleural cancer from 87 European cancer registries in 28 countries were analysed. Relative survival (RS) in 2000-2007 by country/region, age and gender, and over time trends in 1999-2007 were estimated. RESULTS:Lung cancer survival is poor everywhere in Europe, with a RS of 39% and 13% at 1 and 5years since diagnosis, respectively. A geographical variability is present across European areas with a maximum regional difference of 12 and 5 percentage points in 1-year and 5-year RS respectively. Pleural cancer represents 4% of cases included in the present study with 7% 5-year RS overall in Europe. Most pleural cancers (83%) are microscopically verified mesotheliomas. Survival for both cancers decreases with advancing age at diagnosis for both cancers. Slight increasing trends are described for lung cancer. Survival over time is higher for squamous cell carcinoma and adenocarcinomas than for small and large cell carcinoma; and better among women than men. CONCLUSIONS: Despite the generalised although slight increase, survival of lung and pleural cancerpatients still remains poor in European countries. Priority should be given to prevention, with tobacco control policies across Europe for lung cancer and banning asbestos exposure for pleural cancer, and in early diagnosis and better treatment. The management of mesothelioma needs a multidisciplinary team and standardised health care strategies.
Authors: M D Chirlaque; D Salmerón; J Galceran; A Ameijide; A Mateos; A Torrella; R Jiménez; N Larrañaga; R Marcos-Gragera; E Ardanaz; M Sant; P Minicozzi; C Navarro; M J Sánchez Journal: Clin Transl Oncol Date: 2017-07-17 Impact factor: 3.405
Authors: Soumaya Ben Khedher; Monica Neri; Alexandra Papadopoulos; David C Christiani; Nancy Diao; Curtis C Harris; Susan Olivo-Marston; Ann G Schwartz; Michele Cote; Anita Koushik; Jack Siemiatycki; Maria Teresa Landi; Rayjean J Hung; John McLaughlin; Eric J Duell; Angeline S Andrew; Irene Orlow; Bernard J Park; Hermann Brenner; Kai-Uwe Saum; Angela C Pesatori; Isabelle Stücker Journal: Int J Cancer Date: 2017-05-10 Impact factor: 7.396
Authors: M Rodríguez-Barranco; E Salamanca-Fernández; M L Fajardo; E Bayo; Y-L Chang-Chan; J Expósito; C García; J Tallón; P Minicozzi; M Sant; D Petrova; M A Luque-Fernandez; M-J Sánchez Journal: Clin Transl Oncol Date: 2018-10-19 Impact factor: 3.405
Authors: Sonia Blanco-Prieto; Loretta De Chiara; Mar Rodríguez-Girondo; Lorena Vázquez-Iglesias; Francisco Javier Rodríguez-Berrocal; Alberto Fernández-Villar; María Isabel Botana-Rial; María Páez de la Cadena Journal: Sci Rep Date: 2017-01-24 Impact factor: 4.379
Authors: Sonia Blanco-Prieto; Leticia Barcia-Castro; María Páez de la Cadena; Francisco Javier Rodríguez-Berrocal; Lorena Vázquez-Iglesias; María Isabel Botana-Rial; Alberto Fernández-Villar; Loretta De Chiara Journal: BMC Cancer Date: 2017-12-05 Impact factor: 4.430
Authors: Giuseppe Lo Russo; Martina Imbimbo; Giulia Corrao; Claudia Proto; Diego Signorelli; Milena Vitali; Monica Ganzinelli; Laura Botta; Nicoletta Zilembo; Filippo de Braud; Marina Chiara Garassino Journal: Oncotarget Date: 2017-04-26